BioSpace News Archive

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company will present additional preliminary safety and efficacy data from one of its ongoing Phase IIa clinical trials with iadademst

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease today announced that the company has been selected to present at the BioNJ COVID-19 Rapid Fire Research Showcase on Friday, June 5, 2020. David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius Biosciences, will pre

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today that the Company has released a pre-launch supply of its proposed FastPack ® SARS-CoV-2 IgG Immunoassay diagnostic test kits to the University of Louisville to conduct validation studies with hundreds of patient samples, as well as for use in re

Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that it has completed the acquisition of Granules OmniChem Private Limited, purchasing the remaining 50 percent ownership interest from its joint venture partner, Granules

Walt Johnston is a proven senior pharmaceutical executive with nearly 30 years’ experience specializing in global strategy. He has extensive P&L experience in delivering significant revenue growth Mr. Johnston spent the last 12 years with Astellas Pharma, most recently as Senior Vice President, Urology and Hospital Business Unit. Prior to Astellas Pharma, he spent 18 years with Pfizer Kenton Stewart , a 30-year industry veteran, brin

Emerging preclinical and clinical literature support MSCs may be appropriate to develop for COVID-19 as well as non-COVID-19 ARDS ImStem’s investigational MSC candidate IMS001, for which FDA recently removed a clinical hold on an IND to begin a human study in multiple sclerosis, to be considered for further development in COVID19 and ARDS from other causes IMS001 is derived from AgeX human embryonic stem cell line ESI 053

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2019 Environmental, Social and Governance (ESG) Progress Report , demonstrating the company’s social impact and responsibility performance. The report includes 2020 goals for specific topics and clear alignment with the United Nations Sustainable Development Goals. For the first time, an external reviewer validated select report content. Th

New HCPCS Level II Code for Exoskeletons Would Be a Significant Step Towards Access to Exoskeletons for Individuals with Spinal Cord Injuries

Novo Nordisk announced that new data from 38 abstracts will be featured from the company’s approved and investigational diabetes medicines at the upcoming 80 th Annual Scientific Sessions of

Published in the American Journal of Physical Medicine and Rehabilitation, the IMPACT study found a 25 percent reduction in total healthcare costs associated with earlier prosthetic care AUSTIN, Texas--( BUSINESS WIRE )-- Hanger, Inc. (NYSE: HNGR) today announced results of its IMPACT study, which evaluates the impact of overall healthcare costs associated with the timing of definitive fitting and delivery of a lower limb prosthesis following amputat